Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma raised $120 million through a private placement and announced positive results from its Phase 3 INDIGO trial for obexelimab in IgG4-RD, although the stock experienced a significant sell-off. Positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS) were presented at the ACTRIMS Forum 2026. The company reported its fourth-quarter and full-year 2025 financial results, planning to submit obexelimab marketing applications and securing up to $250 million in non-dilutive debt financing. A new major risk of shareholder dilution was identified, with a 37% increase in shares outstanding over the past year. Zenas BioPharma filed and completed a follow-on equity offering of $100 million. An equity raise of $300 million further strengthened the company's liquidity. The stock price has shown significant volatility, with a 52-week range between $8.51 and $44.60, and the share price increased by 91.81% from May 5, 2025, to May 4, 2026.

There is no information available to indicate demand seasonality for Zenas BioPharma's products or services. Demand is likely driven by disease prevalence, treatment efficacy and safety, regulatory approvals, and market access, rather than seasonal patterns.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune diseases. The company operates in the Health Technology sector, specifically Drug Discovery, and aims to identify, acquire, and develop product candidates with superior clinical benefits. Its pipeline includes Obexelimab, a bifunctional monoclonal antibody in development for various autoimmune diseases, and Orelabrutinib, a BTK inhibitor in Phase 3 trials for MS and already approved for B cell malignancies in China and Singapore. The company also has earlier-stage programs like ZB014, ZB021, and a TYK2 inhibitor.

Zenas BioPharma is headquartered in Waltham, Massachusetts, and has a global presence with development and medical affairs capabilities in the United States, Europe, and Asia. The company aims to expand its capabilities, particularly in the U.S. and Europe, and has a strong footprint in China through its subsidiaries.

Zenas BioPharma aims to be a global leader in developing therapies for autoimmune diseases, emphasizing its experienced leadership and disciplined approach to product acquisition. Positive trial results contribute to its scientific standing, but investor perception and market expectations can heavily influence its reputation within the financial community, as evidenced by a stock price drop despite positive Phase 3 data.

Zenas BioPharma's stock is held by a mix of institutional, retail, and individual investors. Institutional investors hold approximately 1.34% to 26.46% of the company's stock, while insiders own about 27.59%, and public companies and individual investors hold between 7.29% and 45.95%. Major institutional shareholders include Fmr Llc, SR One Capital Management, LLC, Enavate Sciences GP, LLC, NEA Management Company, LLC, Federated Hermes, Inc., Fairmount Funds Management LLC, BlackRock, Inc., Vanguard Group Inc, Novo Holdings A/S, and Polar Capital Holdings Plc.